464 related articles for article (PubMed ID: 16428439)
1. Essential role for Rac in heregulin beta1 mitogenic signaling: a mechanism that involves epidermal growth factor receptor and is independent of ErbB4.
Yang C; Liu Y; Lemmon MA; Kazanietz MG
Mol Cell Biol; 2006 Feb; 26(3):831-42. PubMed ID: 16428439
[TBL] [Abstract][Full Text] [Related]
2. A naturally occurring secreted human ErbB3 receptor isoform inhibits heregulin-stimulated activation of ErbB2, ErbB3, and ErbB4.
Lee H; Akita RW; Sliwkowski MX; Maihle NJ
Cancer Res; 2001 Jun; 61(11):4467-73. PubMed ID: 11389077
[TBL] [Abstract][Full Text] [Related]
3. Heregulin beta1-activated phosphatidylinositol 3-kinase enhances aggregation of MCF-7 breast cancer cells independent of extracellular signal-regulated kinase.
Tan M; Grijalva R; Yu D
Cancer Res; 1999 Apr; 59(7):1620-5. PubMed ID: 10197638
[TBL] [Abstract][Full Text] [Related]
4. Breast tumor kinase (protein tyrosine kinase 6) regulates heregulin-induced activation of ERK5 and p38 MAP kinases in breast cancer cells.
Ostrander JH; Daniel AR; Lofgren K; Kleer CG; Lange CA
Cancer Res; 2007 May; 67(9):4199-209. PubMed ID: 17483331
[TBL] [Abstract][Full Text] [Related]
5. Heregulin beta1 promotes breast cancer cell proliferation through Rac/ERK-dependent induction of cyclin D1 and p21Cip1.
Yang C; Klein EA; Assoian RK; Kazanietz MG
Biochem J; 2008 Feb; 410(1):167-75. PubMed ID: 17941827
[TBL] [Abstract][Full Text] [Related]
6. Heregulin (HRG)-induced mitogenic signaling and cytotoxic activity of a HRG/PE40 ligand toxin in human breast cancer cells.
Fiddes RJ; Janes PW; Sanderson GM; Sivertsen SP; Sutherland RL; Daly RJ
Cell Growth Differ; 1995 Dec; 6(12):1567-77. PubMed ID: 9019162
[TBL] [Abstract][Full Text] [Related]
7. Heregulin negatively regulates transcription of ErbB2/3 receptors via an AKT-mediated pathway.
Awasthi S; Hamburger AW
J Cell Physiol; 2014 Nov; 229(11):1831-41. PubMed ID: 24692179
[TBL] [Abstract][Full Text] [Related]
8. The efficacy of ErbB receptor-targeted anticancer therapeutics is influenced by the availability of epidermal growth factor-related peptides.
Motoyama AB; Hynes NE; Lane HA
Cancer Res; 2002 Jun; 62(11):3151-8. PubMed ID: 12036928
[TBL] [Abstract][Full Text] [Related]
9. Heregulin-beta is especially potent in activating phosphatidylinositol 3-kinase in nontransformed human mammary epithelial cells.
Ram TG; Hosick HL; Ethier SP
J Cell Physiol; 2000 Jun; 183(3):301-13. PubMed ID: 10797304
[TBL] [Abstract][Full Text] [Related]
10. An heregulin-EGFR-HER3 autocrine signaling axis can mediate acquired lapatinib resistance in HER2+ breast cancer models.
Xia W; Petricoin EF; Zhao S; Liu L; Osada T; Cheng Q; Wulfkuhle JD; Gwin WR; Yang X; Gallagher RI; Bacus S; Lyerly HK; Spector NL
Breast Cancer Res; 2013; 15(5):R85. PubMed ID: 24044505
[TBL] [Abstract][Full Text] [Related]
11. Herstatin inhibits heregulin-mediated breast cancer cell growth and overcomes tamoxifen resistance in breast cancer cells that overexpress HER-2.
Jhabvala-Romero F; Evans A; Guo S; Denton M; Clinton GM
Oncogene; 2003 Nov; 22(50):8178-86. PubMed ID: 14603258
[TBL] [Abstract][Full Text] [Related]
12. Heregulin beta1 drives gefitinib-resistant growth and invasion in tamoxifen-resistant MCF-7 breast cancer cells.
Hutcheson IR; Knowlden JM; Hiscox SE; Barrow D; Gee JM; Robertson JF; Ellis IO; Nicholson RI
Breast Cancer Res; 2007; 9(4):R50. PubMed ID: 17686159
[TBL] [Abstract][Full Text] [Related]
13. Growth regulation of human breast and ovarian tumor cells by heregulin: Evidence for the requirement of ErbB2 as a critical component in mediating heregulin responsiveness.
Lewis GD; Lofgren JA; McMurtrey AE; Nuijens A; Fendly BM; Bauer KD; Sliwkowski MX
Cancer Res; 1996 Mar; 56(6):1457-65. PubMed ID: 8640840
[TBL] [Abstract][Full Text] [Related]
14. Epidermal growth factor receptor, c-erbB2 and c-erbB3 receptor interaction, and related cell cycle kinetics of SK-BR-3 and BT474 breast carcinoma cells.
Brockhoff G; Heiss P; Schlegel J; Hofstaedter F; Knuechel R
Cytometry; 2001 Aug; 44(4):338-48. PubMed ID: 11500850
[TBL] [Abstract][Full Text] [Related]
15. EGF receptor inhibitors increase ErbB3 mRNA and protein levels in breast cancer cells.
Grøvdal LM; Kim J; Holst MR; Knudsen SL; Grandal MV; van Deurs B
Cell Signal; 2012 Jan; 24(1):296-301. PubMed ID: 21951604
[TBL] [Abstract][Full Text] [Related]
16. Stimulation of beta1-integrin function by epidermal growth factor and heregulin-beta has distinct requirements for erbB2 but a similar dependence on phosphoinositide 3-OH kinase.
Adelsman MA; McCarthy JB; Shimizu Y
Mol Biol Cell; 1999 Sep; 10(9):2861-78. PubMed ID: 10473632
[TBL] [Abstract][Full Text] [Related]
17. Tea polyphenol (-)-epigallocatechin 3-gallate suppresses heregulin-beta1-induced fatty acid synthase expression in human breast cancer cells by inhibiting phosphatidylinositol 3-kinase/Akt and mitogen-activated protein kinase cascade signaling.
Pan MH; Lin CC; Lin JK; Chen WJ
J Agric Food Chem; 2007 Jun; 55(13):5030-7. PubMed ID: 17539658
[TBL] [Abstract][Full Text] [Related]
18. Heregulin regulates cytoskeletal reorganization and cell migration through the p21-activated kinase-1 via phosphatidylinositol-3 kinase.
Adam L; Vadlamudi R; Kondapaka SB; Chernoff J; Mendelsohn J; Kumar R
J Biol Chem; 1998 Oct; 273(43):28238-46. PubMed ID: 9774445
[TBL] [Abstract][Full Text] [Related]
19. Heregulin-mediated ErbB2-ERK signaling activates hyaluronan synthases leading to CD44-dependent ovarian tumor cell growth and migration.
Bourguignon LY; Gilad E; Peyrollier K
J Biol Chem; 2007 Jul; 282(27):19426-41. PubMed ID: 17493932
[TBL] [Abstract][Full Text] [Related]
20. Localization of phosphorylated ErbB1-4 and heregulin in colorectal cancer.
Mitsui K; Yonezawa M; Tatsuguchi A; Shinji S; Gudis K; Tanaka S; Fujimori S; Sakamoto C
BMC Cancer; 2014 Nov; 14():863. PubMed ID: 25416285
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
